Anbio Biotechnology Class A Ordinary Shares Cash Flow Conversion Efficiency
Anbio Biotechnology Class A Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has a cash flow conversion efficiency ratio of 0.093x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Million) by net assets ($17.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Anbio Biotechnology Class A Ordinary Shares (2021–2025)
Cash flow conversion efficiency of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Anbio Biotechnology Class A Ordinary Sha for real-time trading data and today's change.
Anbio Biotechnology Class A Ordinary Shares Cash Flow Conversion Ratio Explained
Anbio Biotechnology Class A Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Anbio Biotechnology Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their cash flow conversion efficiency. Also see Anbio Biotechnology Class A Ordinary Sha market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mayfair Gold Corp
V:MFG
|
-0.176x |
|
Tachan Securities Co Ltd
TWO:6020
|
-0.043x |
|
Wellgistics Health, Inc. Common Stock
NASDAQ:WGRX
|
0.227x |
|
Horizon Gold Ltd
AU:HRN
|
-0.016x |
|
Saniona AB
ST:SANION
|
-0.125x |
|
Deep Fission, Inc. Common Stock
NASDAQ:FISN
|
-0.288x |
|
Ordinary Fully Paid Deferred Settlement
AU:BTRDA
|
N/A |
|
Orvana Minerals Corp.
TO:ORV
|
0.525x |
Annual Cash Flow Conversion Efficiency for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual cash flow conversion efficiency of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. Review Anbio Biotechnology Class A Ordinary Sha (NNNN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.16 Million | $-6.74 Million | -0.223x | -284.68% |
| 2024-12-31 | $17.19 Million | $2.08 Million | 0.121x | +99.61% |
| 2023-12-31 | $14.82 Million | $898.37K | 0.061x | -82.90% |
| 2022-12-31 | $12.55 Million | $4.45 Million | 0.355x | -78.50% |
| 2021-12-31 | $2.54 Million | $4.18 Million | 1.649x | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more